Lester Murray Antman dba SimplyRich increased its position in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 465.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,423 shares of the company's stock after buying an additional 30,806 shares during the period. Lester Murray Antman dba SimplyRich's holdings in Dr. Reddy's Laboratories were worth $590,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Farther Finance Advisors LLC raised its position in shares of Dr. Reddy's Laboratories by 43.2% in the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company's stock valued at $36,000 after buying an additional 137 shares during the last quarter. POM Investment Strategies LLC raised its position in shares of Dr. Reddy's Laboratories by 400.0% in the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after buying an additional 1,820 shares during the last quarter. Independence Bank of Kentucky raised its position in shares of Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company's stock valued at $44,000 after buying an additional 2,220 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in shares of Dr. Reddy's Laboratories in the third quarter valued at approximately $60,000. Finally, Van ECK Associates Corp raised its position in shares of Dr. Reddy's Laboratories by 64.3% in the third quarter. Van ECK Associates Corp now owns 823 shares of the company's stock valued at $64,000 after buying an additional 322 shares during the last quarter. Institutional investors and hedge funds own 3.85% of the company's stock.
Dr. Reddy's Laboratories Trading Down 2.8 %
RDY stock traded down $0.40 on Friday, hitting $13.60. 1,802,113 shares of the company were exchanged, compared to its average volume of 1,994,837. Dr. Reddy's Laboratories Limited has a twelve month low of $13.36 and a twelve month high of $16.89. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The business's fifty day moving average is $14.73 and its two-hundred day moving average is $15.30. The stock has a market capitalization of $11.35 billion, a price-to-earnings ratio of 21.65 and a beta of 0.50.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. As a group, research analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on the stock. StockNews.com lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th. Barclays dropped their price target on shares of Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. Finally, Nomura lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th.
Check Out Our Latest Report on Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Profile
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Further Reading
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
